HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human leukocyte antigen type as a risk factor for nonmelanomatous skin cancer in patients after renal transplantation.

Abstract
Renal-transplant recipients are at an increased risk for developing nonmelanomatous skin cancer (NMSC). Recipient human leukocyte antigen (HLA) type has been suggested as a possible risk factor. We studied the association between HLA type and posttransplant NMSC in 2,433 renal-transplant recipients in a Northern climate, for whom HLA type and clinical follow-up were available. One hundred six (4.3%) patients developed NMSC between 1984 and 1997. Of previously reported HLA-associated risk factors, only HLA A11 showed an increased incidence of posttransplant skin cancer, at 8% (P=0.0137, odds ratio 2.03 with 95% confidence interval 1.11-3.53) in 1998. This effect persisted at follow-up, in a limited reanalysis in 2004. HLA A11 may be a useful marker, in some populations, for identifying at the time of transplantation those patients that are at an increased risk for NMSC and who may therefore be good candidates for preventative clinical trials.
AuthorsAdam Bock, Robin L Bliss, Arthur Matas, Jane A Little
JournalTransplantation (Transplantation) Vol. 78 Issue 5 Pg. 775-8 (Sep 15 2004) ISSN: 0041-1337 [Print] United States
PMID15371688 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • HLA Antigens
  • HLA-A Antigens
  • HLA-B Antigens
Topics
  • Adult
  • Female
  • HLA Antigens (classification)
  • HLA-A Antigens (immunology)
  • HLA-B Antigens (immunology)
  • Histocompatibility Testing
  • Humans
  • Kidney Transplantation (immunology)
  • Male
  • Retrospective Studies
  • Risk Factors
  • Skin Neoplasms (epidemiology, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: